into parts. I commentary will my on results divide quarter three Rob. first our Thanks,
of will status current in interactions research particular I focusing the describe Research with Merck First, clinical regulatory Laboratories, our and on agencies. operational
the some that highlight will achieved the outline hope what we year I to and results during achieve of of first as quarter will progresses. the Second, we some important
we comment address on help I that specifically the COVID-XX have pandemic. we Finally, the hope what and taken to will actions
operational our status. with So begin let me
time clinical SARS-CoV-X included an became As in team COVID-XX that to our putting China, place supplies developing clinical team, infusion made monitoring alternative preparations virtually operations maintain to early clinical global in Operating supplies, strengthening including agents, clinical for our reported Wuhan, overall prepositioning processes data and in what of point, developing manage deliveries, advanced the processes recognized clinical cases, pandemic. been home the schedule. infections to our virtual management importance organization sites. operations the some the our investigational These quality over including preparations and and enable has trial able network, were
But we trials new enrollment reduced continuing certain in clinical and not in jurisdictions. enrollment some across launch most halted to cases have jurisdictions. We are have
future, patients the Europe, enrolled that agencies entirely forward. we MRL our be with our cannot what These in are moving East, processed interact. XXX our pandemic substantial now, the owed and programs XX more spanning numbers are provide five the progress across I to Africa across predict new government the jeopardy. in XXXX our broad for team work not will organizations Middle a of regulatory logs examples, is teams of Indeed, and continents, As than objectives clinical March, course This extraordinary set whom month reassurance database in the of although very our of sites.
to Turning now research accomplishments. important
of quarter of our KEYTRUDA high non-muscle to ability patients continue began the first FDA monotherapy invasive cancer related of with we treatment the risk, improve and previously, as XXrd certain cancer, therapy. to approval indication to with noted KEYTRUDA bladder the generate data As for important KEYTRUDA
greater of cancer, KEYNOTE-XXX KEYTRUDA analysis combination treatment in X expressed data of with standard pathologic a improved progression-free whose provided triple-negative KEYNOTE-XXX result combination breast the with This alone from tumors than improves breast chemotherapy studies response triple-negative in our complements which first-line interim as treatment XX. patients of An complete of metastatic alone score chemotherapy chemotherapy the surgery rate equal chemotherapy the with cancer. to KEYTRUDA versus undergoing in for plus PD-LX patients versus pivotal proportion in or the neoadjuvant survival Phase study a demonstrated combined that
in upcoming detail expect to an medical describe We meeting. results at these
during study mismatch improved monotherapy dual the our primary KEYNOTE-XXX in had the in deficiency current endpoint X to survival, indication quarter, DNA to evaluation overall relapsed once vedotin. lymphoma. Phase the with Hodgkin with survival which repair called compared demonstrated study compared survival the customary MSI in adult strongly We or results And Hodgkin patients progression-free classical demonstrated evaluation high brentuximab colorectal to in will in survival whose patients as as data metastatic or cancer, the trial, also the as KEYNOTE-XXX our of overall KEYTRUDA of with so announced that with data standard classical treatment announced first-line permit evidence Also chemotherapy or monotherapy These lymphoma, of of which The phenotype. we endpoint. DNA support of tumors continue are a microsatellite is study of the permit study continue improved our progression-free instability, refractory results the mature. KEYTRUDA an unresectable will
in PD-X indication that irrespective recall completed University therapy review the MSI the collaboration in tumor Johns the approval as what tumor very whose also per a directed greater certain is will first KEYTRUDA have priority Hopkins agnostic colleagues regard quarter, to of with mutational FDA identification Most in gained biomarker a XXXX of tumor tumors burden high agnostic responsiveness. of a we the as that potential first high from with end for At use of type. the status of the tumor a we DNA, of received we XX than for indication, second megabase mutations equal at patients
to upcoming at reviewed of these forward meetings look in presenting scientific data and all peer journals. We
engaged As also discussions I've data. these regulatory agencies regarding in are with we indicated,
Research be use a we on Response from form Finally, with dosage Letter their the part prior based resubmitted at our and for will Meeting announced six today. all have which our modeling last to approval week study, every that we American of that milligram Cancer weeks in new Complete Association of FDA, have KEYTRUDA based discussed in for both application emerged later in data indications responded the XXX upon the across discussions and adults, KEYNOTE-XXX have information
AstraZeneca inhibitor. of our We've also partnership Lynparza with progress seen in PARP leading our important
or results the PROfound ATM all repair, key we in following or important announced cancer, our in of for as prostate in statistically mutations BRCAX, the of castration-resistant shows enzalutamide men with have BRCAX recombination abiraterone gene, tumors of from which Lynparza are endpoint therapy. metastatic homologous improvement genes trial, last treatment DNA related compared which with overall whose survival week, a Just new significant secondary
from tumors of in for PROfound the patients we yet primary example whose October studies result the you DNA Oncology Medical data benefit defined of provides have another I’ll presented remind The mutations. Meeting therapy Society of at Lynparza European the repair in XXXX. that
in PROfound expect details the perhaps will week. announced, very tier not We near though of the the future, those medical top study, published just the be journal in this
PDUFA versus study, with ovarian FDA quarter. women combination should Phase the plus treatment a bevacizumab the I -- review date with that advanced by maintenance second overall Lynparza of in PAOLA-X X alone the to note first-line the also respect cancer of is examining in trial the our under Lynparza bevacizumab for
approval next from survey as longstanding without who therapy our tumor neurofibromatosis results important approval inoperable type of plexiform ago known with neurofibromis. is X Koselugo symptomatic, complete approved at weeks transduction first is the part selumetinib selected this therapy of The two which important of Koselugo cannot our with who mentioning I AstraZeneca, of generically signal in for are patients colleagues first suffering collaboration identified inhibitor. the
in Meeting X ejection investigational a population areas. Bayer study Earlier Beyond oncology, to soluble worsening for by in we composite with The Phase event. results England kind hospitalization vericiguat, of with therapy last This collaboration on an Journal which Cardiology judged complications. at as therapeutic very further well suffered established heart also high in in that programs the College with advanced the fraction placebo, reduced opportunity of other patients The at demonstrated guanylate our New month. heart data important compared had failure cardiovascular we published the had failure present including of VICTORIA just the given or American endpoints and its to study the quarter, virtually add the in who of Medicine first risk were as at cardiac agonist presented treated represents provided with when death benefit as cyclase colleagues performed
we distant investigational Details with results during antagonist also gefapixant, XX our PXXX program, cough. X our future. in chronic presented and frequency published in these be longstanding reduced the too that of the Phase will not patients the cough Also announced quarter hour in
type the established Pfizer, endpoint achieved VERTIS and non-fatal Merck its for treatment adverse infarction the X jointly events These of administration or outcomes X study major primary disease, trial. diabetes cotransporter patients sodium-glucose conducted first of event non-inferiority as we metabolic CV the CV of the and in Phase cardiovascular X versus were compared time In an Finally, and or myocardial of oral inhibitor just cardiovascular in for by have area, placebo SGLTX announced STEGLATRO stroke. this events. results with defined death atherosclerotic to non-fatal vascular disease
key alone The doubling versus STEGLATRO time heart met. of creatinine superiority or the hospitalization and of death CV serum composite of failure, endpoints secondary placebo the not CV for to for for composite death renal were or baseline of death, from dialysis/transplant
reduction a XXth Detailed not hypothesis June failure consistent with safety While a at the hospitalization XXth observed in for Scientific STEGLATRO to are of that pre-specified heart studies. testing, on was American Session. STEGLATRO. was Association’s CV be scheduled reported statistical in with virtual of VERTIS for results Diabetes presented profile previous The
COVID-XX describe the pandemic. I of an have past the during impact will at the now activities quarter on developing that directed course could treatments
have upon XXX vaccine a it vaccine. than for broad-based manufacturer for development embarked that more SARS-CoV-X we leading is As a years, surprise no program
me these in difficult the development Vaccine many context. and investigation. years extraordinarily requires is results customarily proper Let put of
have noted Research by only efforts, despite seven earned that previously of past pathogens quarter Merck been these directed human against Laboratories. have unaddressed the vaccines developed As were Four seven registration. century, there enormous others during
relevant have this experience we And so area. in
of our there say help as commitment was the Health Africa. produce and outbreaks million that vaccine, Republic has developed in of West emergency can Organization rapidly provide the and protection Guinea, extraordinary and use to workers the the Congo then ERVEBO, The Ebola World many our healthcare proud and required most Nevertheless, other from in virus, and required Zaire a efforts of as authorization building been the -- to jurisdictions. year. of doses address Leone, to we're of recent factory involved a well an hundreds under demonstrated per multiyear X vaccine program development which employees ERVEBO from strain from registration of development Democratic Sierra with
completely at with new X/XXth that in the are X,XXX to however, time COVID-XX With must vaccine this a manufacturer tasked devoted the plan times the we we ERVEBO, pandemic, vaccine scale. and we to creating
capable with safe made, to with with of We the the on from typically speed and efforts progress of with and creating I effective that we humility. challenge act SARS-CoV-X ultimately this to that a to particular that be it's immune inducing which critical allow comprehensive be invented. develop globally. can manufacture know approached response can coronavirus of potent develop neutralizing We mindful I investment. am to will vaccine a deployed will vaccines experience indeed and also understanding a but also say that have vaccine optimistic But to us that enthusiasm this imperative requires long of urgency. We're Based decades design,
With mind, effective characterize this efforts immune to infection. SARS-CoV-X we first supported in have to responses
collect with diagnosed yesterday, cells with Institute multiple hospital, sera over points patients and others partnered Stanford As time at numerous Biology, we we Seattle, the have from Providence with COVID-XX. to for scientists announced in in Systems Swedish and the health University all system,
the these we’ve used proven in coronavirus. vaccines that desirable will available of from made will and generate this derived to immunity With position in to be with past. analyses Data have thoughtful correlates platforms vaccines worldwide, us we been the to researchers selecting themselves, cipher qualities to to respect
difficulty Of guarantee the comments course, in my vaccines, of light these in of developing will to the effective I of regarding successful prove cannot approaches you any prior that near-term.
contract assist would of discussions at vaccines and have are as potential in ever And internal scale. manufacturers those an production we this that surely no appropriate can in collaborators new could doubt the manufacture should resources who of committed laboratories to in rank initiative undertaken. identify the what these with We've most vaccine also challenging are our you process. worked that support own our scientists to However,
studying vaccines, be deployed for antiviral more we search drugs potential engaged our could Beyond are also rapidly. that in
these does too like collaboration address compounds Time at been very to challenge. detail. companies other that describe to in identified community that would permit to we prove has global programs laboratories, have Here in programs of and I biopharmaceutical evaluated laboratories not beneficial. open own this mention our could Instead, have me to the
colleagues our with as also we interactions are advice Within large us and contacted many through and of consortium possibly active their many with led trying we MRL, the own have the that companies through Institutes National Health both can, small, to assistance as of by and for help programs.
wish I of working that of tirelessly that pandemic. life. breakthrough is express and will Merck the than close research does today. extend COVID-XX and mission into by emphasizing it Merck means medicines vital has to ameliorate here This for pursuit improve my all at in vaccines translate to mission gratitude never I seemed our colleagues my more to at to a
the call back Peter. to now I'll return
